Prothena Corporation plc 2020 Form 10-K Summary
Business context and reporting period
Prothena is an Ireland-incorporated, late-stage biotechnology company focused on therapies for diseases involving protein dysregulation, including rare amyloidoses and neurodegenerative diseases. This Form 10-K covers the year ended December 31, 2020; quarterly information includes the fourth quarter ended December 31, 2020.
The pipeline included wholly owned birtamimab for AL amyloidosis, PRX004 for ATTR amyloidosis, and Alzheimer’s disease programs including PRX012, plus partnered prasinezumab with Roche and tau, TDP-43, and an undisclosed target with Bristol-Myers Squibb.
Financial performance and liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Total revenue | $0.9 million | $0.8 million | 5% |
| Research and development expense | $74.9 million | $50.8 million | 47% |
| General and administrative expense | $38.7 million | $35.7 million | 8% |
| Total operating expenses | $113.6 million | $86.5 million | 31% |
| Operating loss | $112.7 million | $85.7 million | 31% increase |
| Net loss | $111.1 million | $77.7 million | 43% increase |
| Basic and diluted loss per share | $2.78 | $1.95 | Higher loss |
| Net cash used in operating activities | $80.4 million | $53.0 million | Higher use |
| Cash and cash equivalents | $295.4 million | $375.7 million | Down $80.3 million |
Revenue consisted of $0.6 million of collaboration revenue and $0.3 million of license revenue. No products were commercially approved or sold, and gross margin is not meaningful for the development-stage business. Interest income fell to $1.4 million from $8.2 million because of lower cash balances and interest rates.
At December 31, 2020, total assets were $333.0 million, total liabilities were $149.0 million, and shareholders’ equity was $184.0 million. The filing does not identify conventional interest-bearing debt; liabilities primarily included $110.2 million of deferred revenue and $17.8 million of operating lease liabilities. Working capital was $273.4 million.
Cash used in investing activities was $0.2 million, while financing activities provided $0.2 million from stock-option exercises. Cash and cash equivalents plus restricted cash totaled $298.1 million at year-end. Management stated that cash and cash equivalents were sufficient to meet obligations for at least the next twelve months, but additional capital will be required to fund longer-term development and potential commercialization.
Material changes versus the prior comparable period
- R&D expense increased $24.0 million, primarily because of higher manufacturing costs for PRX005, birtamimab and PRX012, higher Roche collaboration costs, and higher consulting expense.
- Operating expenses increased $27.1 million, and net loss increased $33.5 million. The 2019 period included a $61,000 restructuring credit; no restructuring charges were recorded in 2020.
- Cash declined by $80.3 million, primarily reflecting operating cash use of $80.4 million.
- Roche-related collaboration revenue declined from $0.8 million to $0.6 million, while $0.3 million of license revenue was recognized in 2020.
- Prasinezumab’s Phase 2 PASADENA study did not meet its primary objective, although management reported signals on several secondary and exploratory endpoints. Roche and Prothena nevertheless planned a Phase 2b study.
- PRX004 Phase 1 results reported in December 2020 showed slowing of neuropathy progression and improvements in cardiac systolic function in seven evaluable patients, but the small, early-stage dataset remains preliminary.
Guidance, outlook, commentary and risks
Management expected R&D expense to increase in 2021 as birtamimab and PRX004 advance into later-stage studies. The company planned to initiate or support AFFIRM-AL, a registration-enabling Phase 3 study of birtamimab; a Phase 2b prasinezumab study led by Roche; a Phase 2/3 PRX004 study; and Phase 1 studies for PRX005 and, later, PRX012. Management also expected potentially significant partner payments and up to six IND filings over the following three years, but these payments and development milestones are uncertain.
In January 2021, the FDA agreed to a Special Protocol Assessment for AFFIRM-AL. The SPA concerns trial design and does not guarantee efficacy, regulatory approval, or receipt of milestone payments.
Major risks include continuing losses, the need for additional capital, potential shareholder dilution, uncertain clinical and regulatory outcomes, COVID-19-related trial and manufacturing disruptions, reliance on Roche and BMS, dependence on third-party manufacturers and clinical research organizations, intellectual-property challenges, reimbursement uncertainty, competition, cybersecurity and data-privacy exposure, and retention of key personnel.
Contractual obligations at year-end totaled $30.8 million, comprising $19.1 million of operating leases, $10.9 million of purchase obligations and $0.8 million under license agreements. These amounts exclude indeterminate future cost-sharing obligations under the Roche agreement. The company reported no material legal proceedings and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Whether AFFIRM-AL enrollment, execution and mortality results support approval of birtamimab.
- Whether Roche advances prasinezumab through Phase 2b and later-stage development, and whether related milestones or cost-sharing obligations arise.
- Whether PRX004’s later-stage ATTR-cardiomyopathy study confirms the preliminary Phase 1 findings.
- The company’s cash runway, timing and terms of any equity, debt or strategic financing.
- Whether BMS exercises U.S. or global rights for any collaboration program and whether milestone or royalty revenue is realized.
- The impact of COVID-19, manufacturing dependencies, trial delays and regulatory requirements on development timelines and cash use.
- Potential dilution from outstanding options, which totaled approximately 8.7 million shares at year-end, and future equity issuances.